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INTRODUCTION 
INTRODUCTION 
 
 Third stage of labour commences with the delivery of the fetus and 
ends with the delivery of the placenta. In view of the maternal risk, the third 
state of labour is the most important phase of parturition. Although it occupies 
an insignificant period of time compared with many hours devoted to labour, 
this short period involves many hazards for the maternal life and health. 
Prolonged third stage of labour is often associated with its related 
complications and increased risk of maternal mortality and morbidity. 
 
 In a developing country like ours postpartum haemorrhage contributes 
appreciably to maternal illness and is a leading cause of maternal death. WHO 
statistics suggest that 25% of maternal deaths are due to postpartum 
haemorrhage. The primary aim in the management of postpartum 
haemorrhage should be its prevention. Several methods have been developed 
to encourage early delivery of the placenta and thereby reduce the risk of 
postpartum haemorrhage. 
 
 
 Uterine atony accounts for about 80% of cases of PPH (Predivelle and 
Elboume 1990). There are several factors which may predispose to uterine 
atony, include overdistended uterus, multipara, prolonged labour, antepartum 
haemorrhage etc. 
 By following protocols of active management of third stage of labour, 
atonic Postpartum haemorrhage should be identified early and action should 
be prompt. The obstetric team could prevent it if atony is there which may be 
attended immediately. 
 
 The present study was designed to evaluate and compare the efficacy 
of oxytocic drugs Inj oxymetrin 1amp im and rectally administered 
T.Misoprostal 800 mcg Inj oxymetrin 1amp contains oxytocin 5 IU and 
Ergometrine maleate 0.5mg 
  
 
 
 
 
 
 
 
AIM OF THE STUDY 
AIM OF THE STUDY 
 
 
1. To evaluate the efficiency of Inj oxymetrin l amp Im in third stage of 
labour as a prophylactic oxytocic drug. 
 
2. To study the effect of Inj.Oxymetrin in III stage critical events.  
(i) Duration of III stage.  
(ii) Blood loss of III stage. 
(iii) Complication of III stage. 
 
3. Comparison of Inj. oxymetrin with Rectal misoprostal in III stage 
management. 
  
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
REVIEW OF LITERATURE 
 
 One of the primary objectives of third stage of labour is prevention of 
postpartum haemorrhage. 
 
 Active management of third stage is usually implemented as a package 
including. 
 
 Early oxytocic therapy (with delivery of the anterior shoulder or 
shortly after delivery of the baby. 
 
 Early cord clamping and placental delivery by controlled cord 
traction following signs of placental separation. 
 
 Oxytocices include syntocinon, methyl ergometrine and prosta 
glandins. -Bonner 
 
Recent review of randomised trials showed a significant reduction in 
the risk of postpartum blood loss of 500ml (or) more for women receiving the 
combination drug syntometrine (Oxytocin and ergometrine) when compared 
with oxytocin 5 units Im. The advantage was smaller but still significant 
(Bonner – 21). 
 
In another randomised double blind prospective study, Intramuscular 
syntometrine was better choice than syntocinon in the management of third 
stage of labour. 2 Inj syntometrine not only reduced blood loss after delivery 
but was associated with a 40% reduction of in risk of PPH and the need for 
repeat oxytocin injection. It’s use is however contra indicated in women with 
hypertensive disorders. Rectal misoprostal 600 mg was significantly less 
effective than 10 units Im syntocinon in active management of third stage 
(17th studd). 
 
In a larger uncontrolled study misoprostal 1000 mg given rectally was 
effective in 16 of 18 women unresponsive to usual oxytocin. The mean 
response time was 14 minutes – Williams 21 (Abdul Aleem and associated 
2001 Brien and collegues 1997). 
 
Villar and coworkers found in their systematic review that oxytocin 
and ergot preparations administered during third stage of labour was more 
effective than misoprostal for prevention of PPH. 
 
Syntomctrine given In. immediately after the delivery of the child is 
associated with a small but statistically significant reduction in PPH compared 
to giving oxytocin alone (Prevention of PPH 70 Fogsifocus Prof. P.K. 
Sekharan). 
 
Cochrane database comparing the effects of oxytocin and 
syntometrine. The analysis showed that there was a significant reduction in 
the risk of postpartum haemorrhage 500 to 1000ml by using syntometrine 
when compared to oxytocin 5 units Im (Mcdonald et al 2000) - Arulkumaran 
– Second). 
 
The oxytocic response of  
¾ Iv ergometrine is 41 seconds. 
¾ Im ergometrine in 7 minutes 
¾ Im syntometrine in 2 ½ minutes  (Ian Donald) 
¾ maximum action for rectal misoprostal was achieved in 
21minutes. 
 
 
In a study published in British journal of obstetrics and Gynaecology 
of 2198 vaginal single ton deliveries, it was concluded that administration of 
combination of oxytocin ergometrine at the end of second stage of labour was 
significantly more effective in preventing postpartum haemorrhage also it was 
found that administration of oxytocin – ergometrine combination after 
delivery of fetal head was significantly more effective in preventing 
postpartum haemorrhage compared with administration after the placenta was 
expelled. 
 
Prostaglandins are well known to be useful in treatment of postpartum 
haemorrhage (Bigrigg et al 1991). Misoprostol PGE1 analogue has a long 
shelf life and does not require any storage conditions. 
 
Drape estimation Vs visual assessment for estimating postpartum 
haemorrhage. 
 
John H stroger Jr. Hospital of cook county chicago USA. 
A randomized controlled study was performed with 123 women 
delivered at District hospital, Belgaum, India. The women were randomized 
to visual or drape estimation of blood loss. Result – The visual estimation of 
blood loss was 33% less than the drape estimate. They have concluded drape 
estimation of blood loss is more accurate than visual estimation and have 
particular utility in the developing world. 
 
Reducing PPH: 
 Oxytocics include syntocinon, methyl ergometrin and prostaglandins. 
 
1. Randomised comparison of Im syntometrine with rectal Misoprostal 
400 mcg for management of III stage of labour was done by Dept of 
O&G Natalsprult Hospital Johannessburg (Bamiyboyaa Merrell 
DA) Duration of III stage, postpartum blood loss and postpartum 
haemoglobin estimation were similar. 
 
2. Department of O&G Royal free and universal college London 
School U.K. The objectives of study is to compare Im Syntometrine 
plus syntocinon versus rectal Misoprostal 800 mg in prevention of 
PPH.  
 
The primary outcome measured was whether haemorrhage ceased with 
in 20 minutes of administration of first line treatment. Conclusion – 
Inj, syntometrine plus syntocinon and rectal misoprostal was equally 
effective in prevention of Postpartum haemorrhage. 
 
3. Department of O&G Ainsham university Cairo Egypt. They 
conducted a study with of rectal misoprostal and compared the 
effectiveness with Im Oxytocin & ergometrine. 
 
Clinical and haemorrhagic parameters were compared using ‘t’ and 
‘chi’ square test. Results in both groups were well matched and had 
similar duration of III stage of labour. Postpartum hypertension was 
more in oxymetrin group. 
 
4. Department of O&G the Chinese University of Hong Kong Prince 
of Whales Hospital Station. A total of 2058 patient with singleton 
pregnancy, low risk for postpartum haemorrhage and vaginal delivery 
were randomized to receive of 2 inj, syntometrine (or) 600 mg 
misoprostal for management of III stage of labour. There was no 
significant difference between 2 groups in mean blood loss, incidence 
of postpartum haemorrhage and fall in haemoglobin concentration. The 
need for additional oxytocin injection was higher in misoprostal group. 
Shivering and transient pyrexia were more common in misoprostal 
group.  
 
5. Department of O&G university of Sydney New South Wales. 
Randomized trial to compare efficacy of Im syntometrin with oral 
misoprostal 400 mcg. Main out come measured blood loss, use of 
second uterotonic agent, difference in Hblevel from antepartum to 
postpartum. 
 
Increase in blood loss and rate of Postpartum haemorrhage >500 ml in 
misoprotal group. Use of second uterotonic agent is higher in 
misoprostal group. Inference. Oral misoprostal 400 mcg is significantly 
less effective than the  Inj. syntometrine 
 
6. British Journal of O&G Jan 2001 Vol 108. Cochrane database 
studies comparing the effect of use of oxytocin and syntometrine. 
Advantages of syntometrine was smaller but significant in decrease in 
postpartum haemorrhage of 500 – 1000ml. No difference seen in large 
postpartum haemorrhage. Need for blood transfusion manual removal 
of placenta were similar. 
 
7. JC Schellenberg Department of O&G Geneva university hospital. 
They have done a study comparing use of rectal administration of 1 gm 
misoprostal with oxytocin and ergometrine.  Duration of III stage and 
blood loss in III stage were similar in both groups. But diastolic 
hypertension was increased in syntometrine group. 
 
8. The Salford Third Stage Trial. Study of Oxytocin plus ergometrine 
versus oxytocin alone in the active management of III stage. 
 
Oxytocin plus ergometrine is more effective than oxytocin alone in the 
prevention of PPH. But ergometrine component caused nausea, 
vomiting and raised BP. 
  
 
 
 
 
 
 
 
 
THIRD STAGE OF LABOUR 
 
THIRD STAGE OF LABOUR 
 
It commences with the delivery of the fetus and ends with the delivery 
of the placenta. Average duration of third stage of labour is around 15 
minutes.  
 
Signs of Placental Separation 
 Uterus becomes globular and firmer. 
 Sudden gush of fresh blood from the vagina. 
 Uterus rises in the abdomen because the placenta having separated, 
passes down into the lower uterine segment where its bulk pushes the 
uterus upward. 
 Extra vulval lengthening of cord. 
 
Physiology of Third Stage 
 Uterine contractions continue after birth of the fetus and intrauterine 
pressure continues to be rhythmically raised. 
 Uterus spontaneously contracts around its diminishing contents. 
 Sudden diminishing in uterine size is inevitably accompanied by a 
decrease in the area of placental implantation. 
 Separation of placenta results primarily from disproportion created 
between the unchanged size of the placenta and the reduced size of the 
underlying implantation site. 
 Two  methods of placental delivery  
o Maternal lower edge of the placenta presents at the vulva – 
Dirty Duncan Method. 
o Placental fetal surface appears first at vulva – Shiny Shultz 
Method 
 
 Blood loss after placental delivery is minimised by  
o Effective contraction of the uterine muscles  
o Blood vessels supplying placental site are compressed by 
oblique fibres of middle layer of the myometrium. 
o Thrombosis of open ends of blood vessels at the placental site 
 
The degree of compression of the vessels depends on the force acting on 
the vessels. 
 
Force obeys the Young Laplace relationship F = 2T 
            r 
F = The compressive force acting on the blood vessels 
T = Wall tension (generated by uterine contraction) 
r  = Radius of the uterus 
 
It is essential that the radius of the uterus be made small by emptying 
the uterus from any blood or placental tissue and increasing the wall tension 
of the uterus (T) by giving Ecbolics - Oxytocics. This is the scientific basis of 
the initial treatment and the prevention of primary PPH. 
Active management of third stage 
Active management of third stage of labour include 
1.  Prophylactic use of oxytocic drugs 
2. Early cord clamping 
3. Controlled cord traction for delivery of the placenta. 
 
Use of oxytocic drugs 
The objective of prophylactic oxytocics is to ensure efficient 
contractions of the uterus after the delivery of the fetus, thus minimizing the 
amount of blood loss. 
 
If an oxytocic drug is given before the delivery of the placenta, the 
procedure of controlled traction should be applied for subsequent delivery of 
placenta.  
 
Clamping of the cord 
Active management of the third stage, usually entails the clamping and 
dividing the umbilical cord early. 
 
 DELIVERY OF PLACENTA 
 
 
 
 
 
 
 
 
Delivery of the placenta 
It is usually done by modified Brandt-Andrews method by controlled 
cord traction. 
 
Once the signs of placental separation are recognised the palmar 
surface of the left hand is placed approximately below the level of the fundus. 
The body of the uterus is displaced upwards and backwards, towards the 
umbilicus while by the right hand steady gentle tension is given in downward 
direction until the placenta comes outside the introitus. 
  
 
  
 
 
 
POSTPARTUM HAEMORRHAGE 
 
POSTPARTUM HAEMORRHAGE 
 
Postpartum haemorrhage is defined as a loss of more than 500 ml of 
blood from genital tract following delivery (or) any loss even less than 500 ml 
if associated with hemodynamic changes in the mother.  
 
PPH are of two types: 
 Primary PPH 
Loss of blood in excess of 500ml during the first 24 hours after birth of 
an infant. 
 Secondary PPH 
When blood loss occurs after the first 24 hours upto six weeks, it is 
designated as secondary PPH. 
 
PPH is a major contributor of maternal mortality. It accounts for 25% 
of all global deaths.  
 
Causes of PPH include 
 Atony of the uterus 
 Trauma to the genital tract 
 Coagulation disorder 
 
Uterine Atony 
It accounts for the majority of cases of PPH 76-81 %. Immediately 
after delivery of the infant and placenta, uterine bleeding associated with a 
soft 'boggy' uterus on palpation is characteristic of uterine atony. 
 
A. Predisposing factors include 
  Prolonged labour 
  Uterine overdistension 
  Antepartum haemorrhage 
  Uterine fibroids 
  High parity 
  Excessive (or) prolonged use of oxytocics in labour 
  Magnesium sulphate in labour 
  General anaesthesia mainly halogenated anaesthetics 
  Precipitate labour 
  Chorioamnionitis 
  Uterine abnormalities 
 
Measurement of blood loss 
 After delivery of the baby, the amniotic fluid is allowed to drain away 
and a specially designed blood collection drape was kept in position by 
slipping under woman’s buttock and left in place to collect blood loss over the 
next hour. 
 Blood and clots from the drape is measured in a measuring cylinder 
blood soaked swabs and linen savers are weighed the known dry weight 
subtracted. 
 
Clinical symptoms and signs related to the amount of blood loss 
 
 
Blood Loss % of  
Blood volume 
Systolic Blood Pressure 
mmHg 
Symptoms and signs 
10 – 15 Normal Postural Hypotension mild 
tachycardia 
15 – 30 Slight fall Tachycardia, thirst, weakness 
30 – 40 60 – 80 Pallor, 
Oliguria, confusion, restlessness
40 + 40 – 60 Anuria, air hunger, coma, death 
 
Prophylaxis of PPH 
1. Every pregnant woman should have haemoglobin estimation during 
her antenatal period. Her blood grouping and Rh typing should be 
done.  
2. Antepartum anaemia is corrected. 
3. Certain patients are susceptible to develop PPH in labour and and 
certain conditions predispose to 
PPH which include 
i.  Multi parity 
ii.  H/o. PPH (or) manual removal of placenta. 
iii.  Abruptio placenta 
iv.  Placenta praevia 
v.  Multiple pregnancy 
vi.  Polyhydramnios 
vii.  Intrauterine death with prolonged retention of dead fetus 
viii.  Prolonged labour 
ix.  Difficult labour 
x.  Caesarean section 
4. In the above patients practice active III stage management of labour. 
5. As long as the child is in good condition and there is no need for rapid 
extraction, the body is delivered slowly. This facilities placental 
separation and permits the uterus to retract sufficiently to control 
bleeding. 
6. In cases where uterine atony is anticipated, an IV infusion is set up 
before the delivery 
7. Squeezing and kneading the uterus before the placenta has separated is 
traumatic and harmful. Look for uterine atony. 
8. Careful postpartum observation of the patient is made. 
9. Excessive and prolonged inhalatory anaesthesia should be avoided. 
10. Fibrinogen studies are done incases of placental abruption and retained 
dead fetus. 
11. When haemorrhage is anticipated adequate amounts of blood should be 
cross matched and kept available. 
 
Treatment of Primary Postpartum Haemorrhage 
Most maternal deaths are avoidable and are due to underestimation of 
blood loss, inadequate volume replacement and delay in operative 
intervention. 
 
Any delay in achieving haemostasis results in terminal coagulopathy. 
At this stage even surgery may be too late. Hence rapid and resolute action is 
paramount. 
Management include 
 General management 
 Specific management 
¾ Medical Management 
¾ Surgical Management 
General Management 
1. Assess the general condition of the patient, the amount of blood loss 
and the degree of hypoxemia. 
2. Vital parameters such as the level of consciousness, pulse rate, blood 
pressure, input / output, level of the uterine funds and amount of blood 
should be monitored. 
3. Two intravenous lines should be set up. 
4. Catheterize the bladder. 
5. Blood should be sent for full blood count and cross matching with a 
request for 4-6 units. 
6. Crystalloids (or) colloids should be given in the meantime 
7. Uterine atony is the cause of PPH in about 80% of cases in the 
meantime, so uterus should be massaged. 
 
Medical Management 
Uterotonic agents in PPH. Usually bleeding will get arrested in 5 – 15 
minutes duration with Oxytocics.  
 
Agent Route of 
Administration 
Dose Comments 
Oxytocin Inravenous 10-40 units in 1000 
ml of RL (or) NS 
Not to exceed 100ml/min 
Methyl 
Ergometrine 
Intramuscular 
intravenous 
0.2mg 6th hourly Avoid in Hypertensive 
patients, cardiac disease 
patients 
15 Methyl PGF2∝ Intramuscular 
intramyometrial 
0.25μg 15 – 90 
mins 
Bronchospasm 
Agent Route of 
Administration 
Dose Comments 
Misoprostol 
(PGE1 Analogues)
Intracervial 
vaginal, rectal 
400μg – 1000μg Nausea, vomiting 
diarrhoea. 
Oxymetrin  Intra Muscular Oxytocin 5 I.U 
Ergometrine 
maleate 0.5 mg 
Avoid in Hypertensive 
patients, cardiac disease 
patients 
 
8. Bimanual compression - Bimanual compression of the uterus 
prevents an increase in the radius of the uterus due to bleeding in the 
uterus. Simultaneously, the uterus is pushed caphalad, which puts the 
uterine arteries under tension and reduces blood flow to the uterus. 
   
Specific Management 
Other methods 
Uterine Package 
It is a controversial subject. It is impossible to pack an atonic uterus so 
tightly that the blood sinuses are closed off. 
 
Uterus simply balloons and fills up with more blood. Despite these anti 
packing arguments, many obstetricians believe that is worth trying to control 
bleeding by this method before more radical measures are employed. If 
bleeding is not controlled cases to be shifted to the tertiary care centre. 
 
Embolization of pelvic arteries 
This technique can be used instead of Hysteretomy or ligation of 
internal iliac artery for the treatment of pelvic haemorrhage. 
 
Procedure 
Under radiologic angiographic control, a polyethylene catheter is 
introduced into the aorta in the Right Femoral Artery. Each internal iliac 
artery is catheterized and occluded with small fragments of gelfoam. 
 
It can be carried out in less than 2hours. 
 
Advantages 
 
 Distal blood vessels are occluded, so that bleeding from reconstituted 
distal vessels is rare. 
 Uterus is retained and further child bearing is possible. 
 
Surgery : 
B Lynch suture for Post partum haemorrhage (Ferguson et al 2000) 
 It is a type of compression suture applied over the uterus to control 
PPH. 
 It has the advantage of maintaining the patient’s child bearing 
potential. 
 
Ligation of the uterine arteries 
Since most of the uterine blood is supplied by the uterine arteries, their 
ligation can control PPH. The collateral supply is sufficient to maintain the 
viability of the organ. 
 
The suture is placed through the myometrium of the lower segment of 
the uterus 2-3 cm medial to the vessels. 
 
Ligation of Internal iliac artery (Allahbadia 1993) 
Ligation of internal iliac arteries at times, reduces the haemorrhage 
appreciably. Most important mechanism of action with this ligation is an 85% 
reduction in pulse pressure in those arteries distal to the ligation, thus turning 
an arterial pressure system into one with pressure in the venous circulation 
and amenable to haemostasis via simple clot formation. 
  
Hysterectomy 
¾ It is performed when all other treatment options have failed. 
¾ In most of the cases, hysterectomy results in the prompt and 
definitive cessation of PPH. 
 
  
 
 
PHARMOCOLOGY OF 
UTEROTONIC DRUGS 
 
 
PHARMOCOLOGY OF UTEROTONIC DRUGS 
 
1. Methylergotamine 
2. Oxytocin 
3. Prostaglandins 
 
Oxymetrin Injection 
(Oxytocin + Ergometrine Maleate injections) 
 
Composition 
Each 1 ml ampoule contains: 
Oxytocin 5 1.U. 
Ergometrine maleate 0.5 mg 
 
Description 
 Oxymetrin injections contain two potent uterine oxytocics i.e. oxytocin 
and ergometrine maleate. Oxytocin is a cyclic nonapeptide secreted by the 
hypothalamus which causes contraction of the uterus, the effect increasing 
with the duration of pregnancy due to proliferation of oxytocin receptors. It is 
chemically designated as Cys-Tyr-lle-Gin-Asn-Cys-Pro-Leu-Gly-Nh2 cyclic 
(16) disulphide with a structural formula of C43H66N12012S2 and a 
molecular weight of 1007.2. 
 Ergometrine maleate is an ergot alkaloid which produces intense 
uterine contractions, especially on the puerperal uterus. It is chemically 
designated as N-[(S)-2-Hydroxy-1 –methylethyl] –D-lysergamide hydrogen 
maleate with a structural formula of C19H23N3O2, C4H4O4 and a molecular 
weight of 441.5. 
 
Pharmacology 
Oxymetrin injections combine the rapid uterine action of oxytocin with 
the sustained uterotonic effect of ergometrine. 
 
 Following intramuscular administration, the latent period for the 
occurrence of the uterine response is considerably shorter with OXYMETRIN 
injections (about 2 ½ minutes) than with ergometrine given alone (about 7 
minutes), whereas the uterotonic effect of Oxymetrin injections lasts for 
several hours compared with only ½ to 1 hour when oxytocin is given alone. 
 
 These properties make Oxymetrin injections suitable for the active 
management of the third stage of labour and for the prevention or treatment of 
postpartum haemorrhage, particularly in situations where for any reason the 
intravenous administration of a uterotonic agent is impracticable. 
 
Pharmacokinetics 
 Oxytocin undergoes enzymatic destruction in the gastrointestinal tract 
but it is rapidly absorbed from the mucous membranes when administered 
buccally or intranasally. It is metabolized by the liver and kidneys with a 
plasma half-life of only a few minutes. Only small amounts are excreted 
unchanged in the urine. 
 
 Ergometrine is reported to be rapidly absorbed after administration by 
mouth and by intramuscular injection, with onset of uterine contractions in 
about 5 to 15 minutes and 2 to 7 minutes respectively. Elimination appears to 
be principally by hepatic metabolism. 
 
Indications 
Oxymetrin Injections are indicated for the following: 
¾ Active management of the third stage of labour (as a means to promote 
separation of the placenta and to reduce blood loss) 
¾ Prevention and treatment of postpartum haemorrhage associated with 
uterine atony. 
 
Contraindications 
Oxymetrin Injections are contraindicated in the following conditions: 
¾ Hypersensitivity to any of the components. 
¾ Pregnancy, labour (except in second stage of labour following the 
delivery of the anterior shoulder). 
¾ Severe hypertension, pre-eclampsia, eclampsia 
¾ Severe disorders of cardiac, hepatic or renal functions; occlusive 
vascular disease; sepsis. 
 
Precautions and Warnings 
 In breech presentation and other abnormal presentations, Oxymetrin 
injections should not be given until after delivery of the child is completed. 
When Oxymetrin injections are used for the management of the third stage of 
labour the possibility of multiple pregnancy must be assessed; Oxymetrin 
injections should not be given until the last child has been delivered. 
 
 Active management of the third stage of labour requires expert 
obstetric supervision. 
 
 If in the treatment of postpartum haemorrhage, bleeding is not arrested 
by Oxymetrin injections, the possibility of a retained placental fragment, or 
soft tissue injury (cervical or vaginal laceration), or of a clotting defect should 
be considered and appropriate measures taken before a further injection is 
given. 
 
 Caution is required in patients with mild or moderate hypertension, or 
with mild or moderate degress of cardiac, hepatic or renal disease (severe 
forms are contraindications). Caution is also required in patients with 
respiratory disease, chronic anaemia and toxaemia of pregnancy. 
 
Drug Interactions 
 Oxymetrin Injections may enhance the pressor effect of 
vasoconstrictors (e.g. of sympathomimetic agents contained in local 
anaesthetics) and potentiate the uterine action of prostaglandins. 
 
 Halothane anaesthesia may diminish the uterotonic effect of Oxymetrin 
Injections. 
 
Adverse Effects 
 Oxymetrin injections may cause nausea, vomiting, uterine 
hypertonicity associated with abdominal pain, headache, dizziness and skin 
rashes. On rare occasions, it may give rise to hypertension, bradycardia, 
cardiac arrhythmias, chest pain or to anaphylactoid reactions associated with 
dyspnoea, hypotension, collapse or shock. 
 
Dosage and Administration  
Active management of third stage of labour 
 1 ml intramuscularly following delivery of the anterior shoulder, or 
immediately after delivery of the child. Expulsion of the placenta, which is 
normally separated by the first strong uterine contraction following the 
injection of Oxymetrin injections should be manually assisted by applying 
gentle fundal pressure. 
 
Prevention and treatment of postpartum haemorrhage: 
1 ml i.m. following expulsion of the placenta, or when bleeding occurs: 
If necessary, the injection of 1 ml may be repeated after an interval of not less 
than 2 hours. The total dose given within 24 hours should not exceed 3 ml. 
 
 Intravenous administration of Oxymetrin injections (0.5 to 1 ml by 
slow injection) is possible, but not generally recommended. It is advisable to 
monitor blood pressure during intravenous administration. 
 
Over Dosage 
 No cause of overdosage with OxymetriniInjections have so far been 
reported. The symptoms most likely to occur would be those of acute 
ergometrine intoxication, nausea, vomiting, hypertension or hypotension, 
vasospastic reactions, respiratory depression, convulsions, coma. Treatment 
would have to be symptomatic. 
 
 Inadvertent administration of the newborn infant has proved fatal. 
Other than general resuscitative measures, no treatment is available. 
 
Presentation 
 1 ml ampoule containing 5 I.U. Oxytocin & 0.5 mg Ergometrine 
maleate. 
 
Storage Conditions 
 Store at 20-80C (Refrigerate, do not freeze). Protect from light. 
 
Ergot Alkaloids 
They are produced by claviceps purpurea a fungus that infects grain. 
These alkaloids affect alpha adrenoceptors, dopamine receptors, 5 HT 
receptors. 
 
Chemistry & Pharmacokinetics 
Two major families of compounds that incorporate the tetracyclic ergo 
line nucleus may be identified. 
1) Amine Alkaloids 
2) Peptide Alkaloids 
 
Pharmacokinetics 
They are variably absorbed from the Gastro intestinal tract. The oral 
dose of ergotamine is about ten times larger than the intramuscular dose. 
 
Amino alkaloids are also absorbed from the rectum and the buccal 
cavity and after administration by aerosol inhaler. Absorption after 
intramuscular injection is slow but usually reliable. 
 
They are extensively metabolized in the body. Primary metabolites are 
hydroxylated in the A ring and peptide alkaloids are also modified in the 
peptide moiety. 
 Pharmacodynamics 
Mechanism of Action 
They act on several types of receptors. Their effects include agonist, 
partial agonist and antagonistic actions at α - adreno receptors and serotonin 
receptors and agonist action at CNS dopamine receptors. 
 
They have a powerful stimulant effect on the uterus that seems to be 
most closely associated with agonist effects at 5 HT2 receptors. 
 
Effects 
1. CNS 
Certain alkaloids are powerful hallucinogens. Bromocriptine directly 
suppresses prolactin secretion from pituitary cells by activating and 
regulating dopamine receptors. 
 
2. Vascular Smooth Muscle 
Ergotamine and related compounds, constrict most human blood 
vessels in a predictable, prolonged and potent manner. 
 
3. Uterine Smooth Muscle 
The stimulation action of ergot alkaloids on the uterus as on vascular 
smooth muscle, appears to combine alpha agonist, serotonin and other 
effects. 
Because of increasing dominance of receptors as pregnancy progresses, 
uterus at term is more sensitive than earlier in pregnancy. 
 
4. Other Smooth muscle organs 
It produces visceral smooth muscle contractions. It does not act on the 
bronchiolar smooth muscle.  
 
Preparations commonly used 
 
Preparations Strength Dosage 
Ergometrine injections 0.5mg/ml 0.2mg/im 0.1 –0.5mg/iv 
Methyl ergometrine 0.2 mg/ml 0.2 mg/ml 0.2 mg sc, im 
& iv 
Syntometrine 0.5 mg methyl 
ergometrine 
in 5 units of oxytocin 
 
Side Effects 
Most common side effects of the ergot derivatives are gastro intestinal 
disturbances including nausea, vomiting and diarrhoea. Activation of the 
medullary vomiting center and of the gastrointestinal serotonin receptors is 
involved. 
 
 Dangerous tonic effects with ergotamineand ergonorine is prolonged 
vasopasm. 
Oxytocin 
It means 'Quick birth'. It is synthesized in the hypothalamus and then 
transported to the posterior pituitary, where they are stored and released into 
the circulation. 
 
Chemistry & Pharmacokinetics 
It is a nine amino acid peptide composed of six amino acid disulfide 
ring and three membered tail containing the carbonyl terminus. 
 
          S   S 
 
Cys - Tyr - lie - Gln - Asn - Cys - Pro - Leu - Gly - NH2 
 
Absorption, Metabolism and Excretion 
 It is usually administered intravenously for stimulation of labor, though 
buccal absorption is possible. 
 
 It is inactive if swallowed, because it is destroyed in the stomach and 
intestine. It is catabolized by the kidneys and liver and plasma t½ is 5 – 10 
minutes. 
 
Pharmacodynamics 
Oxytocin alters transmembrane ionic currents in myometrial smooth muscle 
cells to produce sustained uterine contraction. The sensitivity of the uterus to 
oxytocin increases during pregnancy. Oxytocin causes contraction of myo epithetial 
cells surrounding mammary alveoli which leads to milk injection. 
 
Mechanism of Action and Effects 
Uterus 
It binds to the estrogen receptors on myometrial cell membrane, where 
CAMP is eventually formed and Ca++ is mobilised from sarcoplasmic 
reticulum to activate contractile proteins. 
 
Other Actions 
CVS 
It decreases diastolic blood pressure and a reflex increase in cardiac 
output with tachycardia. 
 
Anti diuretic effect 
Oxytocin in high doses exerts an ADH like action. This can lead to 
water intoxication especially when given with dextrose which is electrolyte 
free. 
 
Side effects 
1) Hypotension, tachycardia 
2) Water intoxication 
3) Increased incidence of neonatal jaundice due to increased red cell 
fragility causing haemolysis. 
 
PROSTAGLANDINS 
Prostaglandins are the most potent naturally occuring bioactive 
autocoids. Vou Euler named this active principle prostaglandin because he 
assumed, it originated in the prostate gland. 
 
Prostaglandin Biosynthesis 
 
Dietary Seed Oils
Linoleic (DGLA)
Dietary Animal 
Lipids
Arachi Donic 
Acid
Dietary
Fish 
Oil
Eicosa
Pentaenoic
Acid
3 Series Pgs
1 Series Pgs
Misoprostol
an analogue of 
PGE1
Cyclic
Endoperoxides
2 Series PG
PGE2, PGE2α 
Degradation 
Degradation of arachidonates occurs rapidly in most tissues, but fastest 
in the lungs. Prostaglandin is catabolized mainly in the kidney. 
 
Actions 
1) CVS 
PGE2 cause vasodilatation but not in all the vascular beds. 
 
PGE2 and F2 stimulate heart by weak direct but more prominent reflex 
action due to fall in BP. 
2) Platelets 
PGI 2 - is a potent inhibitor of platelet aggregation 
3)  Uterus 
PGE2 & PGF2 uniformly contract human uterus. PGs increase tone as 
well as amplitude of uterine contractions. 
4) Bronchial muscle 
They are potent bronchoconstrictors expect PGE2, which is a powerful 
bronchodilator. 
Uses 
¾ Abortion – First trimester termination of pregnancy – PG are used 
¾ Induction and Augmentation of labour 
¾ Cervical priming 
¾ PPH – for control of PPH due to uterine atony specially in patients 
unresponsive to ergometrine and Oxytocin. 
 
Administration of prostaglandins in PPH 
Intramyometrial injections   Uterine lavage   
PgF2 – 250 – 1000 μg (microgram)  PGF2 2000 μg / hr   
PGE2 100 – 200 μg       
15 me PGF2 250 μg     Rectal administration 
       400 – 1000 μg  
Intramuscular     Vaginal Instillation   
15 me PGF2 250 μg     PGE2 20 mg  
  
Side effects 
¾ Nausea. vomiting, watery Diarrhoea. 
¾ Uterine Cramps, flushing, shivering. 
¾ Fall in BP, tachycardia, chest pain. 
 
 
 
  
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
MATERIALS AND METHODS 
 
In this randomized comparative study, 100 patients attending 
Government Rajaji Hospital, Madurai for confinement during the period from 
June 2006 to October 2007 were recruited. They were grouped into 2 groups. 
 
Group A – Prophylactic Inj. Oxymetrin Group – 50 patients 
 
Group B – Prophylactic Rectal Misoprostol Group – 50 patients 
 
Inclusion Criteria 
 Pregnant women with gestational age more than 28 weeks in 
longitudinal lie either vertex (or) breech presentation who deliver vaginally 
including the following risk factors. 
¶ Prolonged Labour 
¶ Instrumental delivery 
¶ Post dated pregnancy 
¶ Anemia 
¶ Elderly primi 
 
 
 
Inj. Oxymetrin 
 
T. Misoprostal 
 
 
Exclusion Criteria 
¶ Abruptio placenta 
¶ Placenta previa 
¶ Twins 
¶ Heart disease 
¶ Asthma complicating pregnancy 
¶ Previous uterine surgery 
 
Methods 
 
Group A 
 50 Patients received Inj. oxymetrin 1 amp Im at the delivery of anterior 
shoulder. 
 
Group B 
 50 Patients were given Rectal Misoprostal 800 μg administered at the 
time of delivery of anterior shoulder. 
 
 In each case, the following parameters were recorded. 
1. Labour – Spontaneous (or) Induced 
2. Labour – Accelerated or not 
3. Duration of I Stage 
4. Duration of II Stage 
Drap Estimation
Measuring Jar
 
5. Mode of Delivery whether labour natural or assisted breech or 
instrumental  
6. Oxytocin used pertaining to 
a. Time of administration, dosage 
b. Duration of III Stage 
c. Amount of blood loss 
7. Side effects of drugs like nausea, vomiting and diarrhea 
8. Need for other oxytocics 
9. Requirement of blood transfusion 
10. Presence of maternal complications after delivery like PPH and 
hypotension. 
11. Coagulation profile before and after deliveries 
 
Measure of Blood Loss 
 The amount of blood loss was measured by collecting the blood in 
blood collection, drape after amniotic fluid drained away. Blood loss was 
calculated 1 gm = 1 ml (Harding 1984). This gives only the approximate 
blood loss during the third stage. 
 
 Blood clot of the size of clenched fist in roughly equal to 500 ml. 
 
 After collecting all the data, the data were tabulated and analysed. 
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 RESULTS 
Profile of cases studied 
Table 1 : Age Distribution 
No of cases in 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
Age in Years 
No % No % 
Less than 20 2 4 2 4 
20 – 24 28 56 25 50 
25 – 29 14 28 20 40 
30 & above 6 12 3 6 
Total 50 100 50 100 
Mean 24.4 23.9 
S.D 4.4 2.9 
‘p’ 0.742 (Not Significant) 
  
Comparing the age distribution in both the groups, majority of the 
patients were between 20-29 years of age 84% (42/50) in Group A and 
90%(45/50) in Group B. Elderly age group contributes to minority of the 
population (i.e.) 12%(6/50) in Group A 6%(3/50) in Group B. Teenage group 
remains the same in both 4%(2/50) in both. 
 
ANTENATAL CARE
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 There is no significant difference in the mean age of the cases in both 
the groups. 
 
Table : 2 Antenatal care 
 
No of cases in 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
 
Antenatal 
care 
No % No % 
Booked 34 68 36 72 
Unbooked 16 32 14 28 
Total 50 100 50 100 
‘p’ 0.8273 (Not Significant) 
 
 In Group A 68% (34/50) were booked and 32% (16/50) were 
unbooked. In Group B 72% (36/50) were booked and 28% (14/50) were 
unbooked. 
 
The antenatal care received by the two groups does not exhibit 
statistically significant difference. 
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Table : 3 Parity 
 
No of cases in 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
 
 
Parity 
No % No % 
Primi 27 54 29 58 
Multi 23 46 21 42 
Total 50 100 50 100 
‘p’ 0.8403 (Not Significant) 
 
In this study, primi gravida were more compared to multigravida.  
¶ In Group A – 54% Primi 46% multi 
¶ In Group B – 58% Primi 42% multi 
 
The parity of the two groups does not have statistically significant 
difference. 
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 Table 4 : Type of Labour 
 
No. of cases in 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
Type of Labour 
No % No % 
Spontaneous 33 66 42 84 
Gel induced 11 22 5 10 
Augmentation 6 12 3 6 
Total 50 100 50 100 
‘p’ 0.0647 (Not Significant) 
 
 
Type of labour was compared in both the groups. Majority of the 
patients in the groups had spontaneous onset of labour. (Group A 66%(33/50) 
Group B 84%(42/50). 
 
Labour was induced in 22%(11/50) in Group A and in 10%(5/50) in 
Group B. 
 
Type of Labour in the two groups does not differ significantly. 
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Table 5 : Method of Delivery 
 
No. of cases in 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
 
Method of 
Delivery 
No % No % 
Labour Natural 45 90 43 86 
Outlet forceps 3 6 7 14 
Assisted Breech 1 2 - - 
Vacuum 1 2 - - 
Total 50 100 50 100 
‘p’ 0.7583 ( not significant) 
 
In comparing the mode of delivery in both the groups, maximum 
number of patients were delivered by Labour natural 90%(45/50) in Group A 
and 86%(43/50) in Group B. Minimal instrumentation was present 8%(4/50) 
in Group A 14%(7/50) in Group B.  
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Comparison of  outcome parameters in the two groups 
 
Table 6 : Changes in Hb. 
 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
 
Hb. 
Mean S.D Mean S.D 
‘p’ 
 At admission 9.0 0.89 8.96 0.89 0.9252 
(Not Significant) 
After delivery 8.78 0.98 8.64 0.87 0.3677 
(Not Significant) 
 
 
Haemoglobin level at admission is compared to haemoglobin level 
after delivery in both groups. 
 
Statistically there was no significant difference in changes of 
haemoglobin in two groups. 
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Table 7 : Duration of III stage of labour 
 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
 
Duration of III stage of 
labour (in minutes) No. % No. % 
<  2 minutes - - - - 
3-4 minutes 10 20 5 10 
5-6 minutes 16 32 6 12 
7-8 minutes 10 20 4 8 
9-10 minutes 4 8 15 30 
More than 10 minutes 10 20 20 40 
Mean 
S.D. 
7.48 
3.31 
9.86 
3.41 
‘p’ 0.0007 Significant 
 
 20% of patients had III Stage duration upto 4 minutes in Group A 10% 
of Group B also 4 minutes. 
In Group A 80% of patients upto 10 mins. In Group B 60% of patients 
upto 10 mins. In Group A mean duration of third stage – 7.48 minutes. In 
Group B Mean duration of   third stage – 9.86 
The mean duration of third stage of delivery in the Inj. Oxymetrin 
group is significantly lower  than in the Tab.Misoprostol group. 
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Table 8 : Blood loss 
 
Inj.Oxymetrin 
Group 
Tab.Misoprostol 
Group 
 
Blood loss (in ml. ) 
No. % No. % 
0-50 1 2 - - 
51-100 6 12 2 4 
101-150 13 26 3 6 
151-200 13 26 6 12 
201-250 6 12 4 8 
251-300 7 14 11 22 
301-350 - - 12 24 
351-400 - - 7 14 
401-450 - - 1 2 
451-500 1 2 - - 
More than 500 ml 3 6 4 8 
Mean 
S.D. 
224.4 
212.9 
319.4 
194 
‘p’ 0.0001 
Significant 
 
• In Group A 66% had blood loss less than 200 ml 
• In Group B 22% had blood loss less than 200 ml. 
 
• In Group A more than 90% of patients had blood loss less than 
300 ml. 
• In Group B only 52% of patients had blood loss less than 300 
ml. 
 
• Mean Blood loss for Group A – 224.4 ml 
• Mean Blood Loss for Group B – 319.4 ml 
 
• More than 500 ml in Group A – 6% 
• More than 500 ml in Group B – 8% 
 
The mean blood loss in the Inj. Oxymetrin group is  lower  than in the 
Tab.Misoprostol group. This difference is statistically significant.  
 
 
 
 
 
 
 
 
Table 9 (a) 
Post partum complication - Inj. Oxymetrin group 
 
Inj. Oxymetrin group PPH 
No. % 
 > 1000 ml 2 4 
500-1000 ml 1 2 
Nil 47 94 
 
Table 9 (b) 
Post partum complication - T. Misoprostol group 
 
T. Misoprostol Group PPH 
No. % 
> 1000 ml 2 4 
500-1000 ml 2 4 
Nil 46 92 
 
The incidence of PPH is 6% in Group A and 8% in Group B. The 
difference is not statistically significant. 
 
Table 10 
Maternal Side Effects 
 
Group A Group B  
No. % No. % 
Shivering and fever - - 3 6% 
Nausea and Vomiting 4 8% 1 2% 
Increase in BP>10mm H 2 4% - - 
 
 Minor side effects like nausea and vomiting occurred in 8% in Group 
A. Shivering and fever occurred in 6% in Group B. Major side effects like 
increase in BP is found in 4% in Group A Nil in Group B. 
 
Statistical Tools ( To be included at the end of Materials and Methods) 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (EPI 2002). 
  
Using this software, frequencies, percentage, mean, standard deviation, 
x2 and  'p' values were calculated. A 'p' value less than 0.05 is taken to denote 
significant relationship.  
 
 
  
 
 
 
DISCUSSION 
 
DISCUSSION 
 
 Patients undergoing normal progression in labour can become 
abnormal within few minutes and a successful delivery can turn swiftly to 
disaster if post partum haemorrhage enters the scene. 
 
 As the saying goes "prevention is always better than cure", prevent 
Post partum haemorrhage by available excellent oxytocic drugs given by 
different routes. 
 
 Here this study was conducted in Department of Obstetrics and 
Gynaecology, Government Rajaji Hospital, Madurai to assess the usefulness 
of two different groups of drugs Inj. Oxymetrin 1 amp Im and Rectal 
Misoprostal 800 mcg in the active management of third stage of labour. 
 
 In this study 50 patients were given Inj. Oxymetrin 1 amp In at the 
delivery of anterior shoulder. 
 
 Another 50 patients were given rectal misoprostal 800 mcg at the 
delivery of anterior shoulder. 
 
 
Discussion of Profile of  Cases Studied 
Age Group and Patients Selection 
 In our study, the age group of patients included varied from 17-35 
years. Maximum percentage of patients belong to the age group 21-30 years. 
 84% of Group A were between 20-29 years. 
 90% of Group B were between 20-29 years. 
 
 This is similar to a randomised controlled trial of oral misoprostal and 
Im Syntometrine in the management of III Stage of Labour by Department of 
Obstetrics and Gynaecology. The Chinese University of Honkong, Prince of 
Wales Hospital,where the mean age was 28 years. 
 
Antenatal Care 
 In our study in Group A 68% were booked and 32% unbooked. In 
Group B 72% were booked and 28% were unbooked. Antenatal care received 
by the two groups were comparable. 
 
Parity 
 In our study primi gravida were more in both groups compared to multi 
gravida. All were singleton pregnancies. 
 In Group A – 54% primi 46% multi 
 In Group B – 58% primi 42% multi 
 This is similar to study done at chinese university of Hongkong Prince 
of Wales Hospital where primis consisted of 52.7% in Misoprostal group and 
54.3% in Syntometrine group. 
 
Type of Labour 
 In our study majority of patients in both groups had spontaneous onset 
of labour. 
¾ Group A – 66% Spontaenous onset of labour 
¾ Group B – 84% spontaenous onset of labour 
 
 Augmentation with Syntocinon drug were done in Group A – 12% and 
Group B – 6%. 
 
 This is similar to chinese University Study Prime of Wales were 80.9% 
had spontaneous onset of labour in Inj. Syntometrine group 83.9% in rectal 
misoprostal group. 18% were augmented in syntometrine group 15% were 
augmented in misoprostal group. 
 
Method of delivery 
 In our study maximum number of patients were delivered by labour 
natural 90% in Group A 86% in Group B. In Group B minimal 
instrumentation was present 8% in Group A 14% in Group B. 
 This is similar to study done by CMY Choy Wc Hau, WH Tam where 
Inj. Syntometrine was compared to Iv Oxytocin 10 Iu. Here 79.2% of 
Syntometrine  group had spontaneous vaginal delivery. 77.6% of syntocinon 
group had spontaneous vaginal delivery. 
 
¾ Instrumental delivery 20.8% in Syntometrine. 
¾ 22.4% in Syntocinon. 
 
Comparison of outcome parameters in both groups 
Changes in Haemoglobin 
 Here haemoglobin level at admission is compared to haemoglobin 
level after delivery (on 3rd postnatal day) in both groups. 
 
Mean Haemoglobin level of Group A 
¾ At admission is 9 gm% 
¾ After delivery is 8.78 gm% 
 
Mean haemoglobin level of Group B 
 At admission is 8.96 gm% 
 After delivery is 8.64 gm% 
 
 This is similar to study by Chinese University of Hongkong Prince of 
Wales Hospital were pre delivery Hb of Syntometrine 11.8 gms%  
48 hrs post delivery Hb of Syntometrine group 10.5 gm%. 
 
 Predelivery Hb of Misoprostal group 11.9 gm%  
 48 hours post delivery  Hb of Misoprostal group is 10.6gm% 
 
There was no significant difference in changes of haemoglobin 
statistically in above study. 
 
In our study too, there was no significant difference in changes of 
haemoglobin in two groups. 
 
In another study by Department of Obstetrics and Gynaecology Natal 
Spruit Hospital Johannesburg where Im Syntometrine was compared to rectal 
misoprostal post partum hemoglobin estimation had similar difference in both 
groups. 
 
Duration of III Stage of Labour 
 In our study in Group A 80% of patients had duration of third stage 
upto 10 minutes. In Group B 60% of patients upto 10 minutes mean duration 
of third stage in Group A is 7.48 minutes and in Group  B is 9.86 minutes. 
 In a study by Chinese university of Hongkong, the duration of third 
stage was < 10 minutes in 86.2% of cases in syntometrine group. The duration 
is < 10 minutes in 79% of cases in misoprostal group. 
 
Blood Loss 
 In our study 66% of Inj. Oxymetrin group had blood loss less than 200 
ml. Only 22% of Rectal Misoprostal group had blood loss less than 200 ml. 
 Mean Blood loss for Group A – 224.4 ml 
 Mean Blood loss for Group B– 319.4 ml 
 
This is similar to the study by Chinese University of Hongkong, Prince 
of Wales Hospital,  
 Mean Blood loss of Syntometrine group – 254 ml 
 Mean Blood loss of misoprostal group – 290 ml 
 
 In our study more than 90% of patients had blood loss less than 300 
ml. In group B only 52% of patients had blood loss less than 300 ml. 
 
 The incidence of PPH i.e. more than 500 ml in Group A is 6% and 
more than 500 ml in Group B is 8%. This is similar to the study by Chinese 
university, where the incidence of PPH in misoprostal group is around 6.3% 
in syntometrine group is around 4.7%. 
 These results were like Salford Third stage trial where the inference 
was oxytocin plus ergometrine is more effective than oxytocin alone in the 
prevention of PPH. 
 
 These results were also similar to that done in Department of 
Obstetrics and Gynaecology, University, Sydney New South Wales which 
compared Inj. Syntometrine with oral misoprostal 400 mcg. In this trial there 
is increase in blood loss and rate of post partum haemorrhage > 500 ml in 
misoprostal group. Use of second utero tonic agent is higher in misoprostal 
group. Inference – oral misoprostal 400 mcg is significantly less effective 
than Inj. Syntometrine. 
 
 According to Williams, Villar and coworkers found in their systematic 
review that oxytocin and ergot preparations administered during third stage of 
labour was more effective than misoprostal in prevention of post partum 
haemorrhage. 
 
Post partum complications 
 Main postpartum complications studied is post partum haemorrhage 
which required additional uterine atonic and blood transfusion. In our study 
Im Inj. Oxymetrin group, 6% of patients had massive post partum 
haemorrhage. 
 In T. Misoprostal group, 8% of patients had massive post partum 
haemorrhage. So, the incidence of Post partum haemorrhage is lower in Inj. 
Oxymetrine group. In Group A two patients needed blood transfusions three 
patients needed additional uterotonics. In Group B two patients needed blood 
transfusions and four patients needed additional uterotonics.  
 
Maternal Side Effects 
 Minor Side effects like nausea, vomiting, occured in 8% in Group A. 
Shivering and fever occurred in 6% in Group B. Major side effects like 
increase in Blood pressure is found in 4% in Group A nil in Group B. 
 
 
 
 
  
 
 
 
 
 
SUMMARY 
 
SUMMARY 
 
 This study was conducted in the Department of Obstetrics and 
Gynaecology, Government Rajaji Hospital, Madurai. Hundred patients under 
this study were admitted in labour ward and with inclusion and exclusion 
criteria they were segregated into Group A and Group B. 
 
¶ Group A patients were given Inj. Oxymetrin 1 amp Im. 
¶ Group B Patients were given rectal Misoprostal 800 μg. 
 
Results 
) Inj. Oxymetrin reduce the duration of third stage more than 
rectal misoprostal. 
) Inj. Oxymetrin reduce blood loss more effectively than rectal 
misoprostal. 
) Inj. Oxymetrin has side effects like increased BP, Vomitting in 
small number of patients. 
) Prophylactic use of inj. Oxymetrn in active management of third 
stage of labour reduces the blood loss and duration of third stage 
with minimal side effects. 
 
  
 
 
 
CONCLUSION 
 
CONCLUSION 
 
) Inj. Oxymetrin is very effective in the active management of third 
stage labour. 
) It reduces the blood loss and duration of third stage labour 
significantly. In oxymetrin group, 90% of the patients had blood 
loss less than 300 ml. In oxymetrin group the mean duration of III 
Stage was 7.48 minutes. 
) Oxytocic response of Inj. Oxymetrin Im is 2 ½ minutes. 
) On critical evaluation Inj. Oxymetrin is more potent in reducing 
the mean duration of third stage and amount of blood loss than 
Rectal Misoprostal.  
) Because of its cost effectiveness, easy administration and 
avoidance of need for trained personnel, Inj. Oxymetrin Im. can be 
used as a alternative oxytocic agent in the third stage of labour in 
all developing countries. 
) Side effects like nausea, vomiting, increased Blood pressure occurs 
in few patients. 
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PROFORMA 
 
PROFORMA 
COMPARATIVE STUDY OF INJ. OXYMETRIN WITH RECTAL 
MISOPROSTAL IN PREVENTION OF PPH 
 
Name :   Age :   IP.No.  SE Status 
Booked      Obstetric Code 
Un booked 
 
LMP    EDD   Gestational Age 
        
 
EXCLUSION CRITERIA 
Abruption  Twins  Placenta Praevia  Heart Diseases 
 
Asthma complicating   Previous h/o. uterine 
Pregnancy     surgery 
 
History 
H/o. Diabetes, Hypertension, Asthma, Epilepsy, Tuberculosis, 
Jaundice 
 H/o. Repeated MTP 
 H/o. Manual Removal of placenta 
 H/o. Previous surgery 
 H/o. Any chronic drug intake 
 H/o. Any other High Risk Factor 
 
Whether labour was spontaneous (or) induced: 
1. Spontaneous   2. Gel Induction 
Whether labour was accelerated or not 
If accelerated with 
ARM ARM with Oxytocin Oxytocin 
   
 
Duration of I Stage 
Duration of II Stage 
Duration of III Stage 
Induction & Delivery interval 
 
Mode of delivery 
LN Instrumental Assisted Breech 
  
 
 
 
Use of oxytocics during third stage of labour 
Oxytocics used    GP A Inj. Oxymetrin lamp Im 
      GP B Rectal misoprostal 800 mg 
 
Maternal Complications: 
     T.Misoprostol  Oxymetrin  
PPH 
Hypertension 
Shivering & fever 
Nausea 
 
Vomiting 
    
INVESTIGATION : 
 Before Delivery After Delivery 
Hb (Gm %)   
CT (Min)   
 
MASTER CHART 
 
 
ge IP.No AN CARE PARITY 
Hb at 
Admn 
Gm% 
MODE Method 
Duration
(minutes)
Blood 
Loss (mn) 
Hb. After 
deli. Gm% 
Complication
2 32999 Booked Primi 9 Gel LN with Epi 6 31 8.8 Absent 
0 32282 Unbooked Primi 9 Spontaneous LN with Epi 5 190 9 Absent 
1 33400 Unbooked Primi 8.6 Gel LN with Epi 6 230 8.2 Absent 
0 33789 Booked Primi 12.2 Spontaneous LN with Epi 5 120 12.2 Absent 
9 33746 Unbooked Primi 9.8 Spontaneous LN with Epi 12 90 9.8 Absent 
2 
33720 
Unbooked Primi 7.8 Gel LN with Epi 12 290 7.5 
Prolonged induc
time 18 hrs.
3 33842 Booked Multi 7.8 Assisted Breech Assisted breech 10 120 7.5 Absent 
5 
34121 
Booked Primi 8.6 Gel LN with Epi 8 220 8.4 
Prolonged induc
time 16 hrs.
5 35487 Booked Multi 8.8 Spontaneous LN with Epi 5 120 8.8 Absent 
9 34417 Booked Multi 8.5 Spontaneous LN with Epi 4 130 8.4 Absent 
5 35248 Unbooked Multi 9 Gel LN with Epi 8 220 8.8 Absent 
7 35731 Booked Multi 8 Spontaneous LN with Epi 6 100 8 Absent 
8 37712 Booked Multi 10 Spontaneous LN with Epi 5 60 9.8 Absent 
5 37989 Booked Primi 8.6 Spontaneous LN with Epi 11 280 8.4 Absent 
2 37841 Unbooked Primi 9.2 Spontaneous LN with Epi 16 120 9.2 Absent 
3 38595 Unbooked Primi 8.6 Spontaneous LN with Epi 4 180 8.4 Absent 
7 38415 Booked Multi 6.8 Spontaneous LN with Epi 4 130 6.6 4th gravida
3 38889 Booked Primi 9.6 Syntocinon LN with Epi 6 280 9.4 Absent 
2 
42781 
Unbooked Primi 8.8 Gel Outlet 6 470 8 
Prolonged IInd st
1 hr 10 min
4 42567 Booked Multi 8 Spontaneous LN with Epi 8 1080 6.8 PPH 
1 
43418 
Booked Primi 11 Syntocinon Outlet with Epi 4 240 10.8 Absent 
5 43476 Booked Multi 9.4 Spontaneous LN with Epi 12 160 9.2 Absent 
0 43433 Booked Primi 8.8 Gel LN with Epi 5 290 8.6 Absent 
ge IP.No AN CARE PARITY 
Hb at 
Admn 
Gm% 
MODE Method 
Duration
(minutes)
Blood 
Loss (mn) 
Hb. After 
deli. Gm% 
Complication
2 45141 Booked Multi 9 Spontaneous LN with Epi 5 130 8.8 Absent 
0 43433 Unbooked Primi i 8.8 Gel LN with Epi 10 180 9.2 Absent 
3 45149 Booked Multi 8.6 Syntocinon Vacuumacuum 8 290 8.4 Absent 
7 45616 Unbooked Multi 8.6 Spontaneous LN with Epi 15 80 8.6 Absent 
5 35705 Unbooked Primi 8 Syntocinon LN with Epi 15 120 7.8 Absent 
3 60638 Booked Multi 10.8 Spontaneous LN with Epi 4 180 10.6 Absent 
9 61842 Booked Primi 10 Spontaneous LN with Epi 6 180 10 Absent 
2 62109 Booked Primi 10 Spontaneous LN with Epi 6 180 10 Absent 
8 62026 Booked Primi 8.6 Spontaneous LN with Epi 7 150 8 Absent 
2 60821 Unbooked Primi 9 Gel LN with Epi 10 1190 7.4 PPH 
3 
62093 
Booked Primi 9.6 Spontaneous LN with Epi 12 230 9 
Big baby more
than 4 kg 
1 62026 Booked Primi 9.8 Syntocinon LN with Epi 4 160 9.4 Absent 
5 62108 Unbooked Multi 9 Spontaneous LN with Epi 8 80 9 Absent 
0 62592 Booked Multi 9 Spontaneous LN with Epi 4 160 8.8 Absent 
5 62591 Booked Primi 9 Gel LN with Epi 6 130 8.6 Absent 
4 62164 Booked Primi 9 Spontaneous LN with Epi 9 280 8.8 Absent 
9 62584 Booked Multi 9 Spontaneous LN with Epi 8 180 8.6 Absent 
2 
62898 
Booked Multi 9.4 Spontaneous LN with Epi 12 230 9 Absent 
2 62511 Booked Primi 8.4 Gel Outlet with Epi 8 630 7.8 Absent 
5 62648 Booked Primi 8 Spontaneous LN with Epi 12 170 8 Absent 
2 62542 Unbooked Multi 8.8 Spontaneous LN with Epi 8 90 8.8 Absent 
0 62138 Booked Primi 9.2 Spontaneous LN with Epi 6 260 9 Absent 
0 62816 Booked Multi 9 Spontaneous LN with Epi 5 150 8.8 Absent 
0 62848 Booked Multi 9.6 Spontaneous LN with Epi 4 200 9.6 Absent 
2 62807 Booked Multi 8.4 Spontaneous LN with Epi 7 140 8.8 Absent 
9 62144 Unbooked Multi 9.6 Spontaneous LN with Epi 3 120 9.6 Big baby 4kg
0 62797 Unbooked Multi 8 Spontaneous LN with Epi 4 180 8 Absent 
5 45148 Booked Multi 9 Spontaneous LN with Epi 6 390 8.6 Absent 
6 
46148 
Booked Multi 8 Spontaneous LN with Epi 4 250 8 Absent 
ge IP.No AN CARE PARITY 
Hb at 
Admn 
Gm% 
MODE Method 
Duration
(minutes)
Blood 
Loss (mn) 
Hb. After 
deli. Gm% 
Complication
7 46208 Unbooked Multi 7 Spontaneous LN with Epi 6 100 7 Absent 
5 47034 Booked Multi 8.6 Spontaneous LN with Epi 10 280 8.2 Absent 
1 
48923 
Booked Primi 8.6 Gel LN with Epi 12 330 8 
Prolonged induc
> 14 hrs 
0 49390 Booked Primi 9.6 Syntocinon LN with Epi 14 280 9.4 Absent 
1 50101 Unbooked Primi 8.6 Spontaneous LN with Epi 5 190 8.4 Absent 
4 50202 Unbooked Primi 6.8 Spontaneous LN with Epi 10 320 6.4 Absent 
6 49940 Booked Multi 10.2 Spontaneous LN with Epi 10 290 10 Absent 
6 50203 Booked Primi 8.8 Spontaneous LN with Epi 15 320 8.6 Absent 
3 50216 Booked Multi 8.8 Spontaneous LN with Epi 13 340 8.6 Absent 
0 
50177 
Booked Primi 9.6 Gel Outlet 8 520 9 
Prolonged II Sta
1 hr 10 min
4 50409 Unbooked Multi 8.6 Spontaneous LN with Epi 5 270 8.4 Absent 
4 50422 Booked Multi 9.6 Spontaneous LN with Epi 10 1160 8.6 PPH 
7 50200 Booked Primi 9 Gel LN with Epi 10 320 9 Absent 
3 50229 Booked Primi 9 Spontaneous Outlet 12 180 8.4 Absent 
7 50231 Unbooked Multi 8 Syntocinon LN with Epi 12 220 8.4 Absent 
5 50440 Booked Multi 8.6 Spontaneous LN with Epi 10 340 8.2 Absent 
3 50445 Booked Primi 9 Spontaneous LN with Epi 14 240 8.6 Absent 
5 50441 Booked Primi 9.6 Spontaneous Outlet 5 360 9.2 Absent 
8 50504 Booked Primi 11.6 Spontaneous LN with Epi 10 170 11.6 Absent 
2 50519 Unbooked Multi 9.2 Spontaneous LN with Epi 12 280 9 Absent 
0 50234 Booked Primi 9.6 Spontaneous LN with Epi 9 120 9.4 Absent 
5 50444 Booked Primi 12 Spontaneous LN with Epi 15 360 11.6 Absent 
1 50237 Booked Primi 9 Spontaneous LN with Epi 10 240 8.6 Absent 
9 54311 Unbooked Primi 9 Spontaneous LN with Epi 4 1100 8 PPH 
5 53847 Booked Primi 9.6 Spontaneous Outlet 15 340 9 Absent 
1 54301 Booked Primi 9.2 Spontaneous LN with Epi 12 290 9 Absent 
5 54166 Unbooked Multi 8 Spontaneous LN with Epi 3 140 7.6 4th gravida
0 53849 Booked Primi 8 Syntocinon Outlet 15 580 7.6 PPH 
8 54034 Unbooked Multi 7.2 Spontaneous LN with Epi 10 170 7 Absent 
6 55330 Unbooked Multi 8.8 Spontaneous LN with Epi 8 80 8.6 Absent 
ge IP.No AN CARE PARITY 
Hb at 
Admn 
Gm% 
MODE Method 
Duration
(minutes)
Blood 
Loss (mn) 
Hb. After 
deli. Gm% 
Complication
5 55321 Booked Multi 9 Spontaneous LN with Epi 4 120 8.6 Absent 
3 54373 Booked Primi 9.8 Spontaneous LN with Epi 10 280 9.6 Big baby 4.2k
8 54366 Booked Primi 9.4 Spontaneous LN with Epi 13 290 9.2 Absent 
5 
54388 
Booked Multi 8.6 Spontaneous LN with Epi 9 180 8.6 Absent 
4 54328 Booked Multi 9 Spontaneous LN with Epi 12 320 8.6 Absent 
4 62858 Unbooked Primi 9.2 Spontaneous LN with Epi 8 280 9 Absent 
7 62865 Booked Primi 9 Spontaneous LN with Epi 9 160 9 Absent 
0 
72442 
Booked Multi 9.2 Spontaneous LN with Epi 12 380 8.4 
Big baby 
4.3 kg 
1 73642 Unbooked Primi 8.8 Spontaneous LN with Epi 11 260 8.2 Absent 
6 75821 Booked Primi 9 Spontaneous LN with Epi 14 360 8.4 Absent 
0 73342 Booked Primi 8.6 Spontaneous LN with Epi 10 330 8.2 Absent 
3 74109 Booked Multi 8.4 Spontaneous LN with Epi 12 420 8 Absent 
1 74058 Unbooked Primi 9 Spontaneous LN with Epi 11 380 8.6 Absent 
0 74038 Booked Primi 9.2 Gel Outlet 10 280 8.8 Absent 
0 74077 Unbooked Multi 8.8 Gel Outlet 6 340 8.8 Absent 
3 74018 Booked Primi 8.4 Spontaneous LN with Epi 4 360 8 Absent 
0 74027 Booked Primi 9 Spontaneous LN with Epi 16 340 9 Absent 
4 74175 Booked Multi 9.2 Spontaneous LN with Epi 8 320 9 Absent 
 
 
